Compare AbbVie Inc (ABBV) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? AbbVie Inc trades at $254.05 (market cap $449.91B), while Direxion Daily Semiconductor Bull 3X Shares trades at $175.1. The key difference: AbbVie Inc pays a 2.72% dividend while Direxion Daily Semiconductor Bull 3X Shares pays none, and AbbVie Inc is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| ABBV | SOXL | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $261.07 | $300.77 |
52-Week Low | $184.85 | $23.99 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
SOXL, a 3x leveraged semiconductor ETF, trades at $194.65, up 7.26% in 24 hours but remains in a bearish technical trend. Recent volatility includes a 16% single-day drop on July 1, 2026 (24/7 Wall Street), highlighting risks of leveraged decay. News sentiment is mixed, with JPMorgan advocating buying the chip dip while Morgan Stanley notes investor rotation away from semiconductors. Key support lies at $189, with resistance at $200.
Outlook is highly speculative due to leverage amplifying sector swings. Opportunities exist for tactical traders betting on semiconductor rebounds, but risks of rapid decay in choppy markets are severe. Long-term holders face structural erosion from volatility, making SOXL unsuitable for buy-and-hold strategies amid elevated sector uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →
